CD7 and T-cell non-Hodgkin lymphoma: Investigate the safety and efficacy of CD7 CAR-T cells for patients with relapse/refractory CD7+ T-ALL/T-LBL, NK/T cell lymphoma and determine the pharmacokinetics of CD7 CAR-T cells in patients.